Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilenya vs Extavia for visual outcome after optic neuritis in CIS or MS
2011-004787-30Phase 3Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of fingolimod in multiple sclerosis (MS), clinically isolated syndrome (CIS) and optic neuritis (ON) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Latency of multifocal visual evoked potentials in affected eye at 6 months. Started Jul 2012; status: terminated.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)clinically isolated syndrome (CIS)optic neuritis (ON)
Beyond the preview
Go deeper on 2011-004787-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004787-30.